KR102269491B1 - 단회 고용량의 mva가 신생아 및 영아에서 보호 면역 반응을 유도 - Google Patents

단회 고용량의 mva가 신생아 및 영아에서 보호 면역 반응을 유도 Download PDF

Info

Publication number
KR102269491B1
KR102269491B1 KR1020157029515A KR20157029515A KR102269491B1 KR 102269491 B1 KR102269491 B1 KR 102269491B1 KR 1020157029515 A KR1020157029515 A KR 1020157029515A KR 20157029515 A KR20157029515 A KR 20157029515A KR 102269491 B1 KR102269491 B1 KR 102269491B1
Authority
KR
South Korea
Prior art keywords
mva
delete delete
tcid
mice
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157029515A
Other languages
English (en)
Korean (ko)
Other versions
KR20150129027A (ko
Inventor
세드릭 셰미나이
아리아네 폴크만
파울 샤플린
마르크 슈터
Original Assignee
버베리안 노딕 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 버베리안 노딕 에이/에스 filed Critical 버베리안 노딕 에이/에스
Publication of KR20150129027A publication Critical patent/KR20150129027A/ko
Application granted granted Critical
Publication of KR102269491B1 publication Critical patent/KR102269491B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
KR1020157029515A 2013-03-15 2014-03-14 단회 고용량의 mva가 신생아 및 영아에서 보호 면역 반응을 유도 Active KR102269491B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361788722P 2013-03-15 2013-03-15
US61/788,722 2013-03-15
PCT/EP2014/000693 WO2014139687A1 (en) 2013-03-15 2014-03-14 Single high dose of mva induces a protective immune response in neonates and infants

Publications (2)

Publication Number Publication Date
KR20150129027A KR20150129027A (ko) 2015-11-18
KR102269491B1 true KR102269491B1 (ko) 2021-06-25

Family

ID=50389388

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157029515A Active KR102269491B1 (ko) 2013-03-15 2014-03-14 단회 고용량의 mva가 신생아 및 영아에서 보호 면역 반응을 유도

Country Status (17)

Country Link
US (1) US9707291B2 (enExample)
EP (2) EP2968524A1 (enExample)
JP (1) JP6480875B2 (enExample)
KR (1) KR102269491B1 (enExample)
CN (1) CN105101993A (enExample)
AU (4) AU2014231229A1 (enExample)
BR (1) BR112015021781A2 (enExample)
CA (1) CA2905569C (enExample)
EA (1) EA034825B1 (enExample)
HK (1) HK1216860A1 (enExample)
IL (1) IL241059B (enExample)
MX (1) MX376293B (enExample)
MY (1) MY175269A (enExample)
SG (2) SG10201707340XA (enExample)
UA (1) UA126785C2 (enExample)
WO (1) WO2014139687A1 (enExample)
ZA (1) ZA201507017B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968524A1 (en) * 2013-03-15 2016-01-20 Bavarian Nordic A/S Single high dose of mva induces a protective immune response in neonates and infants
WO2015136056A1 (en) 2014-03-12 2015-09-17 Bavarian Nordic A/S Use of oil and water emulsions for increasing b cell responses with modified vaccinia ankara virus
MX2022015489A (es) * 2020-06-10 2023-03-22 Bavarian Nordic As Vacuna de virus vaccinia modificado de ankara (mva) recombinante contra la enfermedad del coronavirus.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100910297B1 (ko) * 2000-11-23 2009-08-03 버베리안 노딕 에이/에스 변형된 백시니아 앙카라 바이러스 변형체
WO2009152969A1 (en) * 2008-06-20 2009-12-23 Bavarian Nordic A/S Recombinant modified vaccinia virus measles vaccine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9117596D0 (en) * 1991-08-15 1991-10-02 John Gibson Lifting Gear Ltd Pulling system
US5471902A (en) * 1994-02-22 1995-12-05 Athenry Enterprises Limited Tuning system for pianos
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
JP4801880B2 (ja) * 2002-04-19 2011-10-26 バヴァリアン・ノルディック・アクティーゼルスカブ 新生仔予防接種用変異ワクシニアウイルスアンカラ
US7501127B2 (en) * 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
NO347468B1 (no) * 2005-02-23 2023-11-13 Bavarian Nordic As Et modifisert Vacciniavirus Ankara (MVA) for anvendelse ved immunisering.
WO2008028665A1 (en) * 2006-09-08 2008-03-13 Bavarian Nordic A/S Phenotypic and genotypic differences of mva strains
US20120135032A1 (en) * 2009-10-08 2012-05-31 Bavarian Nordic A/S Generation of a broad t-cell response in humans against hiv
US9463238B2 (en) * 2011-12-09 2016-10-11 Bavarian Nordic A/S Recombinant poxvirus vector comprising tetanus toxin fragment C
EP2864487B1 (en) * 2012-06-22 2018-12-05 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
WO2014019718A1 (en) * 2012-08-01 2014-02-06 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
EP2968524A1 (en) * 2013-03-15 2016-01-20 Bavarian Nordic A/S Single high dose of mva induces a protective immune response in neonates and infants

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100910297B1 (ko) * 2000-11-23 2009-08-03 버베리안 노딕 에이/에스 변형된 백시니아 앙카라 바이러스 변형체
WO2009152969A1 (en) * 2008-06-20 2009-12-23 Bavarian Nordic A/S Recombinant modified vaccinia virus measles vaccine

Also Published As

Publication number Publication date
BR112015021781A2 (pt) 2017-07-18
CN105101993A (zh) 2015-11-25
WO2014139687A1 (en) 2014-09-18
SG11201507192SA (en) 2015-10-29
AU2020260472A1 (en) 2020-11-26
EA201591803A1 (ru) 2016-02-29
CA2905569C (en) 2023-07-25
MY175269A (en) 2020-06-17
UA126785C2 (uk) 2023-02-08
AU2014231229A1 (en) 2015-09-17
US9707291B2 (en) 2017-07-18
ZA201507017B (en) 2018-12-19
IL241059B (en) 2020-10-29
KR20150129027A (ko) 2015-11-18
AU2019200977A1 (en) 2019-02-28
HK1216860A1 (zh) 2016-12-09
SG10201707340XA (en) 2017-10-30
IL241059A0 (en) 2015-11-30
CA2905569A1 (en) 2014-09-18
MX376293B (es) 2025-03-07
MX2015011388A (es) 2016-02-03
EP3708187A1 (en) 2020-09-16
EA034825B1 (ru) 2020-03-25
AU2022235527B2 (en) 2023-10-26
AU2022235527A1 (en) 2022-10-13
JP2016514114A (ja) 2016-05-19
EP2968524A1 (en) 2016-01-20
US20160030551A1 (en) 2016-02-04
JP6480875B2 (ja) 2019-03-13
NZ711569A (en) 2021-03-26

Similar Documents

Publication Publication Date Title
AU2003239805B2 (en) Modified vaccinia virus ankara for the vaccination of neonates
US7097842B2 (en) Modified vaccinia virus ankara for the vaccination of neonates
US8372622B2 (en) Modified vaccinia virus ankara for the vaccination of neonates
AU2022235527B2 (en) Single high dose of mva induces a protective immune response in neonates and infants
EP1518932A1 (en) Modified vaccinia virus Ankara (MVA) mutant and use thereof
EP3116541B1 (en) Use of oil and water emulsions for increasing b cell responses with modified vaccinia ankara virus
NZ711569B2 (en) Single high dose of mva induces a protective immune response in neonates and infants
Cheminay et al. A single vaccination with non-replicating MVA at birth induces both immediate and long-term protective immune responses

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151014

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190221

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200730

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210329

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210621

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210621

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250522

Start annual number: 5

End annual number: 5